Stephan Grupp, MD, PhD, Chief of the Cell Therapy and Transplant Section in the Division of Oncology, has been elected into the National Academy of Medicine (NAM).

A CHOP research leader received an award from the University City Science Center to help develop a new T-cell based treatment for a childhood cancer.

An alternative, humanized CD19 CAR T product for first relapse of pediatric ALL is being evaluated in a clinical trial at Children's Hospital of Philadelphia.

CHOP researchers analyze how some cancer cells resist a groundbreaking cellular therapy, and have found clues to overcoming that resistance.

The grand opening of CHOP’s new Clinical Manufacturing Facility highlights its role in manufacturing tools for 21st century precision medicine, to bring innovative treatments to patients.

Trials of more game-changing cell therapies for pediatric cancer and other diseases are underway or on the horizon at Children's Hospital of Philadelphia.

A bone marrow transplant saved Kaleo’s life. Today, he’s a dancing machine. His success story is an example of CHOP’s expertise in the field of cellular therapy.

Children’s Hospital of Philadelphia was recognized specifically for significant contributions to the development of a new treatment for a certain pediatric leukemia.

The European Commission (EC) approves Kymriah, the first-ever U.S. FDA approved personalized CAR T-cell gene immunotherapy for aggressive blood cancers.

A leading pediatric oncologist at CHOP, Dr. Grupp is now Chief of the Section of Cellular Therapy and Transplant in the Hospital’s Division of Oncology.